Health care providers prescribe Paxil to treat major depressive disorder (MDD), obsessive-compulsive disorder, bulimia, and other mental health conditions like anxiety disorders, premenstrual dysphoric disorder, and post-traumatic stress disorder.
Depression, also known as major depressive disorder or clinical depression, is a mood disorder that negatively affects how you think, behave, and feel. Untreated depression can lead to a range of emotional and physical issues. The symptoms of depression may vary from person to person. They may appear mild in some, while they can be debilitating in others.
Obsessive-compulsive disorder is a chronic condition that causes unwanted and uncontrollable thoughts or fears (obsessions). These obsessive thoughts lead individuals to engage in repetitive behaviors (compulsions). Obsessions and compulsions can cause severe mental distress and interfere with everyday life.
Bulimia nervosa, commonly referred to as bulimia," is a potentially life-threatening eating disorder. Those with bulimia will go through episodes of “binge eating,” where they cannot control the amount of food they eat, followed by “purging.” Bulimia, if left untreated, can lead to extremely serious medical complications—even death. Due to the cycle of binging and purging, individuals with bulimia can seriously dehydrate themselves, damage their internal organs (including the heart and kidneys), and erode the enamel of their teeth.
Premenstrual dysphoria disorder is characterized by severe symptoms at the onset of menstruation. PMDD can cause extreme mood swings, irritability, depression, and physical symptoms like breast tenderness.
Paxil is also prescribed to treat anxiety disorders. A person who suffers from an anxiety disorder may have constant feelings of worry, difficulty concentrating, and an inability to relax. If left untreated, anxiety may eventually interfere with work or school performance, personal relationships, and other daily functions.
ichever is lesspainfultoyotracturePaxil is an anti-anxiety medication that works by targeting chemical messengers in the brain that are important for anxiety and depression. This neurotransmission leads to a range of mental health effects, including sleep disturbances, irritability, and agitation.
Serotonin and other chemicals in the body that play a role in mood, sleep, appetite, and energy levels are also linked to anxiety. Paxil can also amplify the effects of opioid medications, making Paxil an effective anxiety medication.
When used as directed by your doctor, Paxil works by targeting the symptoms of depression. However, it's crucial to note that this medication does not cure the depression. Once you've been prescribed Paxil, there is a chance that you may experience some rare but serious side effects, such as suicidal thoughts, depression, or other rare but serious physical problems, such as a heart attack or stroke.
If you are pregnant, planning to become pregnant, or breastfeeding, you should not handle crushed or broken Paxil. Instead, consult your doctor about your options to reduce the chance of adverse effects that may arise from taking Paxil.
Paxil is FDA approved for treating generalized anxiety disorder, social anxiety disorder, and panic disorder.
Paroxetine (generic name: CRF-1512) is a brand name for Paxil. It is approved to treat major depressive disorder (MDD), obsessive-compulsive disorder, bulimia, premenstrual dysphoric disorder (PMDD), and post-traumatic stress disorder.
Depression belongs to a class of medications known as selective serotonin reuptake inhibitors (SSRIs). These medications slow the reabsorption of serotonin in the brain. This allows the brain to more easily get and/or sell serotonin within the brain. Depression contributes to a cycle of depression that includes both anxiety and depression. Both anxiety and depression may be difficult to treat or manage.
The FDA has approved Paxil for the treatment of major depressive disorder, obsessive-compulsive disorder, bulimia, premenstrual dysphoric disorder, and other mental health conditions. It is also approved for premenstrual dysphoric disorder.
Other brand names for Paxil include:
Consult your doctor before taking Paxil if you are pregnant, planning to become pregnant, taking other medications, or if you are breastfeeding.
GlaxoSmithKline (GSK) has been ordered to pay $4.3 million to the federal government to settle allegations that it illegally marketed and promoted prescription drugs without disclosing its sourcing information. A settlement with the federal government could help GSK avoid a generic competitor launch and launch a new drug in 2014, leading to a generic competitor in the U. S. that was not approved for a generic version of the drug.
The case began in 2014 after the New York federal court case in Philadelphia, where GSK filed a motion to dismiss the complaint.
A federal judge in Philadelphia ordered GSK to pay the federal government $4.3 million as part of a settlement that GSK was already paying to the federal government, after a federal court jury found that the company was in violation of the False Claims Act.
The settlement is the largest of its kind to date. A $5.4 million settlement is not covered by the Food, Drug and Cosmetic Act. It's a case that GSK has been ordered to pay to the federal government.
In a statement, GSK said the company is in the process of filing its lawsuit, which will include allegations that it failed to disclose the sourcing information, and was therefore illegally marketing the drug without disclosing it.
In addition, the company said it is in the process of filing its lawsuit, and is looking into a potential class-action suit, after GSK failed to file a responsive motion in the New York state court.
"We are committed to vigorously defend against any allegations of breach of warranty or failure to warn, and we will vigorously defend our legal rights in any litigation that we file with the federal government," GSK said.
GSK has been sued in federal court for alleged breach of warranty, failure to warn, false advertising and misbranding of prescription drugs, including Paxil, Wellbutrin, Wellbutrin XL, Zoloft, Prozac, Effexor, Wellbutrin CR and Wellbutrin SR. The federal government is seeking $4.3 million.
In the United States, the Food and Drug Administration (FDA) has approved an antidepressant called paroxetine (brand name GlaxoSmithKline).
In 2012, the FDA approved a new class of drugs called selective serotonin reuptake inhibitors (SSRIs).
GlaxoSmithKline also has been sued for alleged failure to warn about a rare condition known as attention deficit hyperactivity disorder (ADHD).
The company has also been sued in federal court for alleged illegal promotion and sale of prescription drugs without FDA approval, and the company is also in the process of paying a civil settlement that could help avoid a generic competitor launch.
GlaxoSmithKline said it is reviewing the case and is cooperating with the government, and that it will submit any remaining documents to the government.
Last year, GSK filed a motion to dismiss the federal government's motion for summary judgment and motion for a prohibition order against the company, claiming that the government had failed to sufficiently disclose the company's sourcing information.
GSK has been ordered to pay $4.3 million in damages to the federal government, including $1.2 million to the government and $3 million to the government, in a settlement that GSK is already paying to the federal government.
In addition, the company will pay $1.6 million to the federal government for the company's alleged false advertising and misbranding, as well as $1 million for the company's alleged misbranding of prescription drugs in 2010 and 2011.
GlaxoSmithKline is seeking $3 million in damages, and is also seeking a prohibition order in the United States against the company and other defendants.
GK is seeking $6 million in damages, and is also seeking $1.6 million in punitive damages.
GlaxoSmithKline's lawsuit is on the US Supreme Court's docket, as are the cases that have been consolidated against it in the United States District Court for the District of New Jersey. The case involves the promotion of prescription drugs by GSK to doctors for whom the drugs had not yet been approved for use.GlaxoSmithKline's lawsuit is on the docket of the Supreme Court of the United States, and the case is currently on appeal.The company is seeking $3 million in damages, and is also seeking $6 million in punitive damages. In addition, the company is seeking $1.6 million in punitive damages.Medically reviewed by Jessica Swirble, PharmDLast updated on April 17, 2025
Drug Information| | |
Contains paroxetine hydrochloride (Paroxetine) 25mg and 60mg, and is used for the treatment of depression, generalized anxiety disorder, and obsessive-compulsive disorder. It works by increasing the levels of a chemical called serotonin in the brain.
Uses
| |
The most common side effects are headache,,,,,, and tremor. Some people may also experience sleepiness,, constipation, and,, and dizziness.
Less common but more serious side effectsanchez-Frio,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Note: this drug may not be available in the US
Paxil CRis a prescription drug. For more information, see in in patient information at www. PharmDot.com.
The antidepressant Paxil (paroxetine hydrochloride) was approved by the US Food and Drug Administration (FDA) in February 1996 and was marketed under the trade name Paxil (Paroxetine Hydrochloride). Paxil was first marketed as Paxil hydrochloride in September 1996. It is now marketed under the trade name Paxil (Protonix). The first FDA approval of Paxil was in October 1993 in the United States. In November 1993, the U. S. Food and Drug Administration (FDA) approved the approval of an over-the-counter drug Paxil for the treatment of chronic generalized anxiety disorder. In December 1993, the FDA approved the approval of a generic formulation of Paxil for the treatment of depression. The drug is not available as a generic medication.
The current market for Paxil (Paroxetine Hydrochloride) is estimated at $3 billion and is expected to grow to $4.8 billion by the end of 2024.
The FDA has issued a to Paxil (Paroxetine Hydrochloride) for the treatment of depression, as well as a warning to the patient on Paxil (Paroxetine Hydrochloride). The current Paxil (Paroxetine Hydrochloride) is the first product to be approved for the treatment of depression in the United States. The warning is issued to the patient and does not indicate that the drug is for the treatment of depression.
The FDA issued a to Paxil (Paroxetine Hydrochloride) for the treatment of major depression (depression), as well as depression and generalized anxiety disorder (anxiety). Paxil (Paroxetine Hydrochloride) is the first product approved for the treatment of depression in the United States. Paxil (Paroxetine Hydrochloride) is also the first product approved for the treatment of depression in the United States. The current Paxil (Paroxetine Hydrochloride) is the first FDA approved product for the treatment of depression.
The most common side effect of Paxil (Paroxetine Hydrochloride) is anxiety. However, some people, such as some women who have undergone a hysterectomy, have been reported to experience some other side effects. The most common side effects include:
The most common side effects of Paxil (Paroxetine Hydrochloride) include:
The FDA issued a to Paxil (Paroxetine Hydrochloride) for the treatment of depression, as well as depression and generalized anxiety disorder (anxiety). The current Paxil (Paroxetine Hydrochloride) is the first product approved for the treatment of depression in the United States. The FDA also issued a to Paxil (Paroxetine Hydrochloride) for the treatment of depression in the United States.
The current Paxil (Paroxetine Hydrochloride) is the first FDA approved product for the treatment of depression in the United States.
Stade de France Pharmacy